Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Illustrations that have commented on medicine and society have evolved over the last 150 years from being judgmental and harsh towards racial and ethnic minorities to now emphasizing the positive aspects of diversity.